A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Relatlimab and Nivolumab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III-IV Melanoma - RELATIVITY 098

Bristol-Myers Squibb International Corporation0 个研究点目标入组 1,313 人开始时间: 2021年9月1日最近更新: 2024年2月26日

适应症

试验速览

暂无简介。

•- All participants must have been diagnosed with either Stage IIIA (> 1 mm tumor in lymph node)/B/C/D or Stage IV melanoma by AJCC v8 and have histologically confirmed melanoma that is completely surgically resected (free of disease) with negative margins in order to be eligible. All melanomas, except uveal melanoma, regardless of primary site of disease, will be allowed.
•- All participants must have disease-free status documented by a complete physical examination within 14 days prior to randomization and imaging studies within 35 days prior to randomization.
•- Tumor tissue obtained from surgical specimen or biopsy during resection collected within 3 months prior to randomization, with an associated pathology report, must be submitted to the central laboratory prior to randomization.
•- Eastern Cooperative Oncology Group (ECOG) performance status = 1.
•- Participant must be = 18 years of age inclusive at the time of signing the informed consent.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 958
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 355

•- Prior immunotherapy treatment for any prior malignancy: No prior immunotherapies are permitted (such as, but not limited to, anti-programmed death-1 (anti-PD-1), anti-programmed death ligand-1 (anti-PD-L1), anti-programmed death ligand-2 (PD-L2), or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways).
•- Prior treatment with LAG-3 targeted agents.
•- Prior therapy for melanoma except surgery for the melanoma lesion(s) and/or adjuvant radiation therapy for central nervous system lesions.
•- Participants with an active, known, or suspected autoimmune disease. Participants with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.

发起方